Evinacumab for Homozygous Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: ) are associated with hypolipidemia and protection against atherosclerotic cardiovascular disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial hypercholesterolemia. METHODS: In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned in a 2:1 ratio 65 patients with homozygous familial hypercholesterolemia who were receiving stable lipid-lowering therapy to receive an intravenous infusion of evinacumab (at a dose of 15 mg per kilogram of body weight) every 4 weeks or placebo. The primary outcome was the percent change from baseline in the LDL cholesterol level at week 24. RESULTS: The mean baseline LDL cholesterol level in the two groups was 255.1 mg per deciliter, despite the receipt of maximum doses of background lipid-lowering therapy. At week 24, patients in the evinacumab group had a relative reduction from baseline in the LDL cholesterol level of 47.1%, as compared with an increase of 1.9% in the placebo group, for a between-group least-squares mean difference of -49.0 percentage points (95% confidence interval [CI], -65.0 to -33.1; P<0.001); the between-group least-squares mean absolute difference in the LDL cholesterol level was -132.1 mg per deciliter (95% CI, -175.3 to -88.9; P<0.001). The LDL cholesterol level was lower in the evinacumab group than in the placebo group in patients with null-null variants (-43.4% vs. +16.2%) and in those with non-null variants (-49.1% vs. -3.8%). Adverse events were similar in the two groups. CONCLUSIONS: In patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy, the reduction from baseline in the LDL cholesterol level in the evinacumab group, as compared with the small increase in the placebo group, resulted in a between-group difference of 49.0 percentage points at 24 weeks. (Funded by Regeneron Pharmaceuticals; ELIPSE HoFH ClinicalTrials.gov number, NCT03399786.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In total, 65 patients with HoFH were randomized to evinacumab (15 mg per kilogram body weight intravenous) or placebo every 4 weeks. Evinacumab lowered LDL-C by − 49% compared with placebo without a significant increase in adverse events. Evinacumab also significantly reduced ApoB-100 by − 37%, non-HDL by − 52%, total cholesterol by − 48%, triglycerides by − 50%, and ApoC-III by − 90%.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison, evinacumab, a monoclonal antibody against ANGPTL3 that is thought to cause near-total suppression of ANGPTL3 activity, 7,14,15 reduces ApoB levels by >40% in adults with refractory hypercholesterolemia or homozygous familial hypercholesterolemia in its intravenous formulation administered at a dose of 15 mg/kg.14,15”
From Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70 (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ELIPSE HoFH trial, evinacumab significantly reduced LDL-C levels by 49% from baseline in patients with homozygous familial hypercholesterolemia (HoFH)—a population in whom standard lipid-lowering therapies (including statins and PCSK9 inhibitors) are often ineffective due to absent or defective LDL receptors [53].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These findings are confirmed in the recently published ELIPSE trial (Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia), which showed a similar LDL-C lowering effect of Evinacumab in patients with hoFH with null/null and non-null/null variants.20”
From ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report (2021) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationCuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationMolecular genetics of the LDL receptor gene in familial hypercholesterolemia
Hobbs, H. H., Brown, M. S., & Goldstein, J. L. (1992) · Human Mutation · doi:10.1002/humu.1380010602 · Cited by 921
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Self-citationRaal, F. J., Honarpour, N., Blom, D. J., Hovingh, G. K., Xu, F., Scott, R., Wasserman, S. M., & Stein, E. A. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61374-x · Cited by 734
Self-citationKöster, A., Chao, Y. B., Mosior, M., Ford, A., Gonzalez-DeWhitt, P. A., Hale, J. E., Li, D., Qiu, Y., Fraser, C. C., Yang, D. D., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0476 · Cited by 427
ANGPTL3 inhibition in homozygous familial hypercholesterolemia
Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K.-Y., Sasiela, W. J., Chan, K.-C., Brisson, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705994 · Cited by 323
Self-citationShimamura, M., Matsuda, M., Yasumo, H., Okazaki, M., Fujimoto, K., Kono, K., Shimizugawa, T., Ando, Y., Koishi, R., Kohama, T., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000252827.51626.89 · Cited by 297
Cited by
Items 501–600 of 809
Ogunniyi, K. E., Aghasili, C. C., Akinmoju, O. D., Olaiya, V. O., Abib, O. M., Odueke, A., Popoola, H. A., Onyenokwe, V., Onaolapo, D., Usman, A.-A. M., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00762-9 · Cited by 3
“[102].”
FNIP1 variants are associated with favourable metabolism in 1 million humans
Hindy, G., Adam, R. C., Sosina, O. A., Pryce, D. S., Blair, D., Herman, J., Lee, J., Dornbos, P., Mayerhofer, E., Gilly, A., et al. (2026) · Nature · doi:10.1038/s41586-026-10864-2 · Cited by 3
The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs
Ballantyne, C. M., & Catapano, A. L. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i1.7 · Cited by 4
Inhibition of ANGPTL3 as a Target for Treating Dyslipidemias
Watts, G. F., Chan, D. C., & Raal, F. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00027-3 · Cited by 3
Self-citationOlatunji, G. D., Kokori, E., Moradeyo, A. A., Lema, K. F., Ayo, O. R., Obasanjo, O. M., Mustapha, M. J., Stanley, A. C., & Aderinto, N. (2024) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-024-00335-3 · Cited by 3
“Forming an immune complex with evinacumab inhibits ANGPTL3, enhancing the removal of very low-density lipoprotein (VLDL) remnants and ultimately reducing LDL cholesterol levels via a mechanism independent of LDL receptors [10, 17].”
BackgroundTherapeutic Vaccines and Nucleic Acid Drugs for Cardiovascular Disease
Nakagami, H., Hayashi, H., & Morishita, R. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.3.328 · Cited by 3
“41 Moreover, an siRNA targeting angiotensinogen has been developed for hypertension treatment.”
BackgroundQin, R., Ye, L., Duan, L., Li, M., He, W., Mei, X., Li, D., Jin, R., Lv, C., Zhu, M., et al. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01539-8 · Cited by 6
“A similar trend was also observed with evinacumab [19, 21, 27].”
InfluentialA Lipid lover’s Guide to Novel Therapeutics for Lipid and Cardiovascular Risk Reduction
Hritani, R., Hussain, A., Saeed, A., & Agarwala, A. (2021) · Future Cardiology · doi:10.2217/fca-2020-0216 · Cited by 4
New trials in the scene of cardiovascular disease: innovation, controversy, and reassurance
Badimón, L. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab048 · Cited by 3
“In that trial, Evinacumab showed to reduce LDL (–47%) after 24 weeks of treatment when infused intravenously over a period of 60 min, at a dose of 15 mg/kg every 4 weeks.(2) In the trial presented at AHA, the objective was to evaluate whether a subcutaneous administration of the antibody was similarly efficacious and…”
BackgroundCai, Z., Deng, L., Chen, Y., & Ling, Y. (2022) · Endocrine · doi:10.1007/s12020-022-03024-9 · Cited by 3
“Evinacumab, a monoclonal antibody against ANGPTL3, has shown remarkable efficacy in patients with homozygous familial hypercholesterolemia [16].”
BackgroundLipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review
Hassen, L. J., Scarfone, S. R., & Milks, M. W. (2022) · Geriatrics · doi:10.3390/geriatrics7020038 · Cited by 5
“As such, evinacumab has been initially labeled for patients with homozygous familial hypercholesterolemia [54], which is a highly rare disorder (approximately 1 in 300,000) that classically results from homozygous or compound heterozygous pathogenic variants in LDLR, APOB, or PCSK9 leading to minimal intact LDL recept…”
BackgroundCirculating Levels of PCSK9, ANGPTL3 and Lp(a) in Stage III Breast Cancers
Chong, E. W., Joncas, F., Seidah, N. G., Calon, F., Diorio, C., & Gangloff, A. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.09.007 · Cited by 4
A Systematic Review of the Randomized Controlled Trials of Gemcabene and Its Therapeutic Uses
Besekar, S., Jogdand, S., & Naqvi, W. M. (2023) · Cureus · doi:10.7759/cureus.36811 · Cited by 4
“Therefore, the anti-inflammatory properties of gemcabene provide patients with CVD with additional benefits in addition to its LDL-lowering action [2,18].”
BackgroundMonoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups
Wu, N., Li, Z.-F., Lu, M.-Y., & Li, J. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2321374 · Cited by 4
“Evinacumab, a fully human mAb specifically targeting ANGPTL3, has shown substantial reductions in LDL-C levels, even in patients with HoFH [95].”
BackgroundFamilial hypercholesterolaemia and emerging therapeutics
Farias, F. I., Kim, S. M., & Shapiro, M. D. (2023) · Heart · doi:10.1136/heartjnl-2022-321917 · Cited by 4
Emerging therapies in dyslipidaemias
Catapano, A. L. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107229 · Cited by 3
Stankov, S. G., Vitali, C., & Rader, D. J. (2022) · Circulation · doi:10.1161/circulationaha.122.061233 · Cited by 3
Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments
Polychronopoulos, G., Papagiannis, A., & Τζιόμαλος, Κ. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2174524 · Cited by 4
Pirillo, A., Casula, M., Baragetti, A., & Catapano, A. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00001-7 · Cited by 3
White, O., Aligabi, Z., Burks, K. H., Tang, J., Stitziel, N. O., Goldberg, I. J., Remaley, A. T., & Lucero, D. (2025) · doi:10.1101/2025.03.02.640965 · Cited by 4
Blom, D. J., & Gaudet, D. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.502 · Cited by 3
Self-citationKlose, G., Gouni‐Berthold, I., & März, W. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01524-y · Cited by 2
The genetics of autosomal dominant familial hypercholesterolemia
Anderson, S., & Botti, C. (2023) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000930 · Cited by 4
In Silico Description of the Direct Inhibition Mechanism of Endothelial Lipase by ANGPTL3
Montavoci, L., Mariem, O. B., Saporiti, S., Laurenzi, T., Palazzolo, L., Ossoli, A., Guerrini, U., Calabresi, L., & Eberini, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063555 · Cited by 4
“However, at the moment, only one monoclonal antibody, Evinacumab, which recognizes and blocks ANGPTL3, is commercially available and is used for the treatment of familial hypercholesterolemia [16].”
BackgroundAAV8- LDLR Gene Therapy in Ldlr -KO and Homozygous Ldlr p.W483X Mice
Li, Q., Tang, M., Jin, Y., Ju, K., Li, Y., Ju, K., Zhang, S., Zhang, S., & Luan, X. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.164 · Cited by 3
Guo, H., Wang, Q., Wang, Y., Dong, X., Wang, Z., Kang, H., & Cheng, S. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1524697 · Cited by 3
McCarron, É. P., McNeice, A. H., Cash, J., Heneghan, M., & Loughery, C. (2025) · QJM · doi:10.1093/qjmed/hcaf084 · Cited by 2
Alkhairy, A., Xiang, P., Khoo, J. K., Taylor, C. M., & Francis, G. A. (2025) · JACC Case Reports · doi:10.1016/j.jaccas.2025.104648 · Cited by 2
Future of angiopoietin-like protein 3 inhibitors as a therapeutic agent
Marston, N., & Zimerman, A. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001013 · Cited by 3
Tada, H., Takeji, Y., & Takamura, M. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.001 · Cited by 2
Zuin, M., & Bilato, C. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-04234-5 · Cited by 2
Genetic Testing for Children with Familial Hypercholesterolemia
Nagahara, K., Tada, H., & Dobashi, K. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22046 · Cited by 3
Toward an Integrated Therapeutic Approach for Familial Hypercholesterolemia
Balkrishna, A., Agarwal, U., Saxena, S., Sharma, G., & Arya, V. (2026) · Current Medical Science · doi:10.1007/s11596-025-00149-6 · Cited by 2
“[8, 45].”
Mancini, G. B. J., Ryomoto, A., Ruel, I. L., Iatan, I., Genest, J. J., Raal, F. J., Santos, R. D., Chacra, A. P. M., Kennedy, B. A., Brunham, L. R., et al. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120646 · Cited by 2
Self-citationBouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2026.01.001 · Cited by 2
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101725 · Cited by 3
Mombelli, G. G., Pavanello, C., Vicari, F., Moschetti, C., Albertí, A., Calabresi, L., & Sirtori, C. R. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.02.007 · Cited by 2
Dyslipidemia in Diabetes: Navigating a Complex Landscape for Improved Cardiovascular Outcomes
Wahab, R. A., & Mahmood, W. A. W. (2026) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514261422310 · Cited by 2
“92,93 Adverse events that need to be considered include hepato-toxicity, injection site reaction, hepatic fat accumulation, and high cost.”
Katzmann, J. L., & Laufs, U. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01390-7 · Cited by 2
Wulff, A. B., Varbo, A., Nordestgaard, A. G., & Nordestgaard, B. G. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2639678 · Cited by 2
“However, HDL-cholesterol was also lowered in patients receiving evinacumab, likely due to ANGPTL3 inhibition increasing the activity of endothelial lipase [127,128].”
CRISPR gene editing of angiopoietin-like 3: toward one-time precision therapy for dyslipidaemia
Mondal, A. R., & Misra, A. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02605-8 · Cited by 2
Llop, D., & Ray, K. K. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag045 · Cited by 2
Evinacumab with or without lipoprotein apheresis in homozygous familial hypercholesterolaemia
Moriarty, P. M., Wiegman, A., Godin, R., Waldron, A., Rosenson, R. S., Zhao, X.-Q., Pordy, R. C., Raal, F. J., & Gaudet, D. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag182 · Cited by 4
Self-citationAre we underestimating the benefits of lipid-lowering therapies?
Pirillo, A., Casula, M., Olmastroni, E., Scotti, S., Corsini, A., & Catapano, A. L. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100140 · Cited by 2
Zadeh, S. S. T., Toth, P. P., & Banach, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1789019 · Cited by 2
“Two serious adverse events occurred (urosepsis and suicide attempt), and both patients recovered (Raal et al., 2020).”
Homozygous familial hypercholesterolaemia: insights from the Global HICC Registry
Schonck, W. A. M., Mulder, J. W. C. M., Cuchel, M., Reeskamp, L. F., Alnouri, F., Iatan, I., Freiberger, T., Kayıkçıoğlu, M., Tromp, T. R., Reijman, M. D., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag357 · Cited by 2
Self-citationRemnant cholesterol — The transition from biomarker to risk factor
Rosenson, R. S., Velamuri, D. N., Muntner, P., & Goonewardena, S. N. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120755 · Cited by 4
Self-citationHepatic Lipoprotein Production, Cardiometabolic Phenotypes, and Subtypes of Steatotic Liver Disease
Davidson, N. O. (2026) · Circulation Research · doi:10.1161/circresaha.126.327269 · Cited by 2
Arca, M., Björnson, E., D’Erasmo, L., Costanzo, A. D., Bini, S., Minicocci, I., Tramontano, D., Covino, S., Ciarlo, G., Lombardi, M., et al. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70124 · Cited by 2
“This accords with the observation that plasma apoCIII is reduced markedly by evinacumab treat-ment [41].”
Bitencourt, I. C., Zimerman, A., & Marston, N. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01441-z · Cited by 2
“Therapies targeting the ANGPTL axis, including monoclonal antibodies and RNA-based strategies, have led to substantial reductions in atherogenic lipoproteins across different phenotypes of dys - lipidemia [8–15].”
InfluentialTO MARKET, TO MARKET–2021: MACROMOLECULAR THERAPEUTICS
Agard, N. J., Dragovich, P. S., Kelly, R. L., Lim, S. A., Beal, A. M., Moench, I., Chen, S.-J., Gram, A. M., & Kung, P. (2022) · Medicinal chemistry reviews · doi:10.1021/mc-2022-vol57.ch25 · Cited by 2
Universal Pediatric Cholesterol Screening: The Time Has Come!
McGowan, M. P., & Peterson, A. L. H. (2024) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2024.113928 · Cited by 2
Molecular Therapeutics in Development to Treat Hyperlipoproteinemia
Ahmad, M., & Hegele, R. A. (2025) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00768-0 · Cited by 5
“Evinacumab reduces LDL-C by up to 55% in patients with HoFH [73] and by up to 50% in patients with severe HeFH [74].”
Stirnkorb, C., Ney, V., Bergmann, C., & Bald, M. (2025) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2024-0505 · Cited by 2
Bihorel, S., Dingman, R. K., Mendell, J., Wang, Y., Banerjee, P., Pordy, R. C., Davis, J. D., DiCioccio, A. T., & Harnisch, L. O. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70016 · Cited by 4
“In the pivotal phase 3 study in adolescents and adults (NCT03399786), a 47.1% LDL-C reduction from baseline was reported after evinacumab 15 mg/ kg q4w iv infusions for 24 weeks [19].”
InfluentialSelf-citationPediatric Hypertriglyceridemia: Lipoprotein Metabolism, Etiology, and Management
Moriyama, H., & Ham, J. N. (2025) · Current Pediatrics Reports · doi:10.1007/s40124-025-00349-7 · Cited by 3
“…is currently approved by the Food and Drug Administration (FDA) for LDL cholesterol reduction in individuals as young as 5 years with homozygous familial hypercholesterolemia, as it has been shown to lower LDL cholesterol level by approximately 50% in this medically refractory population [64, 65].”
Singh, L., Gašić, V., Komazec, J., Grubiša, I., Popović, L., Rasulić, I., Petakov, A., Mitrović, M., Mihailović, E., Pavlović, S., et al. (2025) · Journal of Medical Biochemistry · doi:10.5937/jomb0-62224 · Cited by 2
“…magnitude of LDL-C reduction is influenced by both the functional class of the LDLR variant (defective versus null,) and adher ence to therapy, while newer LDLR-independent agents such as evinacumab (ANGPTL3 inhibition) offer additional benefit in severe phenotypes, includ ing homozygous FH (40).”
Pechetty, R., Rao, P. S., Deb, T., Shekar, C., & Deepthi, K. (2025) · Indian Journal of Cardiovascular Disease in Women · doi:10.25259/ijcdw_55_2025 · Cited by 2
A narrative review of impacts of apolipoproteins on atherosclerotic coronary plaques
Fukase, T., & Dohi, T. (2026) · npj Cardiovascular Health · doi:10.1038/s44325-026-00104-x · Cited by 2
“Evinacumab, which has inhibited ANGPTL3, was approved in 2021 by both the EMA and FDA for the treatment of homozygous familial hypercholesterolemia 124 .”
Biolo, M., Lupo, M. G., Marodin, G., Portinari, C., Zambon, A., Bertocco, S., Previato, L., Simioni, P., Ferri, N., & Zambon, S. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.03.014 · Cited by 2
LDL-Cholesterol Lowering Therapies: An Update
Humphrey, R., & Bowman, L. J. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm53219 · Cited by 2
Unmet Cardiovascular Risk Beyond LDL-C: A Perspective on Managing Residual Cardiovascular Risk
Kypreos, K. E., Gafencu, A. V., Andreopoulou, O., Zvintzou, E., Marinos, K., Mparnia, V., Alemi, M., Daraban, B. S., Multescu, M. G., Ghinea, M., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19071071 · Cited by 2
“It is currently indicated as an adjunct to other lipid-lowering therapies for patients aged 1 year and older with homozygous familial hypercholesterolemia (HoFH) [38].”
Managed care pharmacist updates for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
Patel, J. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88608 · Cited by 3
Feldman, D. I., Wu, K. C., Hays, A. G., Marvel, F. A., Martin, S. S., Blumenthal, R. S., & Sharma, G. V. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100181 · Cited by 3
Individualized dosing of evinacumab is predicted to yield reductions in drug expenses
ter Heine, R., Rongen, G. A. P. J. M., van Lennep, J. E. R., & Rutten, J. H. W. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.03.004 · Cited by 2
Production and Metabolism of Triglyceride-Rich Lipoproteins: Impact of Diabetes
Pirillo, A., Norata, G. D., & Catapano, A. L. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_7 · Cited by 3
The future of clinical lipidology in the UK
Cegla, J., Datta, D. B. N., Rees, A., Soran, H., & Thompson, G. R. (2024) · Clinical Medicine · doi:10.1016/j.clinme.2024.100026 · Cited by 2
Pussadhamma, B., Wongvipaporn, C., Wutthimanop, A., Nuinoon, M., Porntadavity, S., & Jeenduang, N. (2024) · Scientific Reports · doi:10.1038/s41598-024-57069-z · Cited by 3
OS TIPOS DE TRATAMENTOS ATUALMENTE DISPONÍVEIS PARA DISLIPIDEMIA E CONTROLE DOS TRIGLICERÍDEOS
Nogueira, D. R., Melo, G. C. D. C., Silva, I. D. A. C. E., Moreira, L. E. P., Pedrosa, M. D. S. B., Cardinali, M. D. P., Peron, P. L. V., & Piazzi, R. G. (2024) · EPITAYA eBooks · doi:10.47879/ed.ep.2024264p13 · Cited by 5
Afzal, M., Altaf, H., Faiz, T., Zafar, R., Shoukat, R., Waseem, M., & Aziz, S. (2024) · THE JOURNAL OF MICROBIOLOGY AND MOLECULAR GENETICS · doi:10.52700/jmmg.v5i1.145 · Cited by 2
Use of Evolocumab in Familial Hyperlipidemia With Isolated Heart Transplant
Mackenzie, C. B., Anderson, M., & Shah, K. (2024) · JACC Case Reports · doi:10.1016/j.jaccas.2024.102426 · Cited by 2
Hacışahinoğulları, H., Oyman, G. B., Mutlu, Ü., Dadin, S., Yalın, G. Y., Soyluk, Ö., Gül, N., Beşışık, S. K., Satman, İ., Karşıdağ, K., et al. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2460-7066 · Cited by 2
“Evinacumab reduces LDL cholesterol levels by approximately 50 % in patients with HOFH, regardless of the degree of LDL-receptor function [30].”
ANGPTL3 regulates the peroxisomal translocation of SmarcAL1 in response to cell growth states
Nagai, T. H., Mizoguchi, T., Wang, Y., Deik, A., Bullock, K. H., Clish, C. B., & Xu, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-89552-6 · Cited by 2
Corpataux, N., Aregger, F., Koskinas, K. C., & Gebhard, C. (2025) · Swiss Medical Weekly · doi:10.57187/s.4024 · Cited by 2
Huang, S., Liu, Y., Zhang, J., & Wang, Y. (2025) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2025.2506591 · Cited by 3
“These genes are strongly associated with familial AD [49], and focal AD [50].”
Yuan, Y., Zhao, X., Teng, X., & Zhang, Y. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-5600 · Cited by 2
“Evinacumab, being a very promising one, is a monoclonal antibody that binds to ANGPTL3 with the aim to further reduce the level of LDL-C in homozygous FH patients (20).”
BackgroundSelf-citationKhalaj, R., & Douroumis, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821749-8.00004-5 · Cited by 3
Clinical strategies for reducing cholesterol levels
Lardinois, C. K., & Karr, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00027-4 · Cited by 2
RNA therapies for cardiovascular disease
Laina, A., Vlachogiannis, N. I., Stamatelopoulos, K. S., & Stellos, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822546-2.00003-4 · Cited by 2
Safarova, M. S., Santos, R. D., & Moriarty, P. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00034-0 · Cited by 2
Gaudet, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00035-2 · Cited by 2
Self-citationThe Beneficial Effect of Lomitapide on the Cardiovascular System in LDLr−/− Mice with Obesity
Munkhsaikhan, U., Kwon, Y. I., Sahyoun, A. M., Galán, M., González, A. A., Ait‐Aissa, K., Abidi, A. H., Kassan, A., & Kassan, M. (2023) · Antioxidants · doi:10.3390/antiox12061287 · Cited by 3
“Unfortunately, if not treated, most patients with HoFH do not survive beyond age 30 without medical intervention [11,12], with some deaths recorded even before the age of 5 [13].”
BackgroundGuan, M., Wang, H., Wang, F., Liang, S., Li, L., Wang, B., & Zhang, L. (2024) · Thrombosis Journal · doi:10.1186/s12959-024-00657-w · Cited by 2
Toroghi, M. K., Bosley, J., Powell, L. M., Zhang, Y., Yang, F., Pu, X., Davis, J. D., & Al-Huniti, N. H. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12694 · Cited by 2
Self-citationWorking towards full eradication of lipid-driven cardiovascular risk?
Nurmohamed, N. S., & Stroes, E. S. G. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01600-8 · Cited by 2
“Inhibition of ANGPTL3 with evinacumab was recently shown to be effective in reducing LDL-C levels by 49% in a phase 3 trial with 65 FH patients already maximally treated with lipid-lowering therapies [37].”
BackgroundHyperlipidemia in Children and Adolescents
Michaud, L., Sharedalal, P., Seplowe, M., Rosenzveig, A., Frishman, W. H., & Aronow, W. S. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000465 · Cited by 2
СУЧАСНА ГІПОЛІПІДЕМІЧНА ТЕРАПІЯ (ОГЛЯД ЛІТЕРАТУРИ)
Botsiurko, Y. V. (2022) · Прикарпатський вісник наукового товариства імені Шевченка ПУЛЬС · doi:10.21802/2304-7437-2022-18(66)-120-125 · Cited by 2
Evidence-Based, Mechanistic Approach to the Management of Homozygous Familial Hypercholesterolemia
Rosenson, R. S. (2022) · JACC Case Reports · doi:10.1016/j.jaccas.2022.08.017 · Cited by 3
“At baseline, most patients were treated with a statin (94%), including a high-intensity statin in 77%; ezetimibe was used in 75%, PCSK9 inhibitor in 77%, and lomitapide in 25%.(7) In addition, 34% of patients received LDL apheresis.”
BackgroundSelf-citationLuo, F., Yu, L., Xian, X., Shan, B., & Das, A. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1364170 · Cited by 2
Zhang, P., Wang, K., Hu, T., Xu, M., You, X., Chen, M., Tang, X. L., Hu, H., Jiang, Y., Zhao, W., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202301564rr · Cited by 1
“18 Evinacumab, as a fully human IgG4 mAb against ANGPTL3 derived from transgenic mice, 58,59 has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for treating HoFH (https:// www. fda . gov / ).”
BackgroundDey, H., Agarwal, V., Ali, M. N., Upadhyay, A., Shafieq, S., Dixit, B., Tomar, S., & Tarannum, M. (2024) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v14i4.6533 · Cited by 1
“77 Moreover, the magnitude of triglyceride and LDL cholesterol lowering achieved with evinacumab has been unprecedented, surpassing the effects of conventional lipid-lowering therapies.”
BackgroundDevelopment of Dyslipidemia in Atherosclerosis and Modern Approaches to its Treatment
Blagov, A. V., Sobenin, I. A., Sukhorukov, V. N., Glanz, V. Y., Pleshko, E. M., & Orekhov, A. N. (2024) · The Heart Surgery Forum · doi:10.59958/hsf.7341 · Cited by 1
“%) in patients with homozygous familial hypercholesterolemia [73].”
BackgroundMasana, L., & Ibarretxe, D. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.07.004 · Cited by 2
Homozygote familiäre Hypercholesterinämie - Teil 2
Parhofer, K. G., Vogt, A., Binder, C. J., Ebenbichler, C. F., Greber‐Platzer, S., Harreiter, J., Kassner, U., Klose, G., Lang, I. M., Merkel, M., et al. (2024) · CardioVasc · doi:10.1007/s15027-024-3654-4 · Cited by 1
“…420 mg s.c. Nach In der doppelblinden, randomisiert kontrollierten ELIPSEStudie mit 65 Pa tienten mit HoFH konnte nach 24 Wo chen durch Evinacumab eine relative LDLCReduktion um 49 % im Ver gleich zu Placebo beobachtet werden, ausgehend von einem Basis LDLCWert von 255,1 mg/dl [11].”
Śliwa, N., Dądela, B., Kawalska, E., Majewska, E. M., Gnitecki, S., Borowski, M., Janczura, S., Zielonka, K., Markowski, M., & Jasińska, J. (2025) · Quality in Sport · doi:10.12775/qs.2025.42.61202 · Cited by 1
Catapano, A. L., Filardi, P. P., Oliva, F. G., Agnello, L., Baragetti, A., Berteotti, M., Bilato, C., Calabrò, P., Cesaro, A., Gori, A. M., et al. (2025) · Biochimica Clinica · doi:10.23736/s0393-0564.25.00077-9 · Cited by 1
Арманович, А. А., Kaktursky, L. V., Urazova, O. I., Трофименко, А. И., Sukiasyan, L. M., Коган, Е. А., Демура, Т. А., & Вачиковна, П. Н. (2025) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2025-2-124-140 · Cited by 1
Evinacumab Improved the Homozygous Familial Hypercholesterolemia Lipid Metabolism: A Case Report
Matsuda, T., Osaki, Y., Matsumoto, N., Nakajima, R., Murayama, Y., Sugano, Y., IWASAKI, H. O., Mathis, B. J., Sekiya, M., & Shimano, H. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65925 · Cited by 1
“In this case, TG was reduced by −129 to −103 mg/dL (−71.5% to −66.8%), consistent with or exceeding the results from a phase 3 trial 7) , suggesting that differences in LPL activity alone may not fully explain LDL-C variability.”
InfluentialBreaking barriers: Innovative therapies for managing homozygous familial hypercholesterolemia
Huang, S.-J., Huang, P. H., Song, N.-N., Jia, X.-H., Gao, H., Lu, Z., & Wen, X. (2025) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2025.105003 · Cited by 1
Antibody-Based Therapeutics for Hypercholesterolemia
Tomlinson, B., & Chan, P. (2025) · Biologics · doi:10.2147/btt.s500456 · Cited by 1
Metadata
- Authors
- Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D. A., Khilla, N., Pordy, R., Weinreich, D. M., Yancopoulos, G. D., Zhang, Y., & Gaudet, D.
- Affiliations
- University of the Witwatersrand (ZA)
- Regeneron (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-08-20
- Volume
- 383
- Issue
- 8
- Pages
- 711-720
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3061843793
- Semantic Scholar
- 9f8bdc77b195a0ec05f5cb5d0662d5a8c5e0b865
- Cited by
- 793
- References
- 24
- Citations by year
- 2026: 126 · 2025: 129 · 2024: 139 · 2023: 123 · 2022: 130 · 2021: 123 · 2020: 22
- FWCI
- 91.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- evinacumab, homozygous familial hypercholesterolemia, ANGPTL3, LDL cholesterol lowering, monoclonal antibodies, lipid-lowering therapy, atherosclerotic cardiovascular disease prevention
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Adolescent, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Child, Double-Blind Method, Female, Homozygote, Humans, Hyperlipoproteinemia Type II, Infusions, Intravenous, Cholesterol, LDL, Male, Middle Aged, Mutation, Receptors, LDL, Least-Squares Analysis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.